Theoretical mechanisms by which immunoglobulin therapy might benefit myasthenia gravis
- 30 November 1989
- journal article
- review article
- Published by Elsevier in Clinical Immunology and Immunopathology
- Vol. 53 (2) , S83-S91
- https://doi.org/10.1016/0090-1229(89)90073-1
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Definition of Myasthenogenic Sites of the Human Acetylcholine Receptor Using Synthetic PeptidesaAnnals of the New York Academy of Sciences, 1987
- Antiidiotopic Modification of the Anti-Acetylcholine Receptor Immune Response and of Experimental Autoimmune Myasthenia Gravis in Lewis RatsAnnals of the New York Academy of Sciences, 1987
- High‐Dose Gammaglobulin Therapy of Generalized Myasthenia GravisAnnals of the New York Academy of Sciences, 1987
- Immunomodulation in Myasthenia Gravis by High-Dose Intravenous 7-S ImmunoglobulinsAnnals of the New York Academy of Sciences, 1987
- Autoantibodies to Receptors by an Autoantiidiotypic RouteAnnals of the New York Academy of Sciences, 1987
- Serum Antibodies and Monoclonal Antibodies Secreted by Thymic B-Cell Clones from Patients with Myasthenia Gravis Define Striational AntigensAnnals of the New York Academy of Sciences, 1987
- Stabilization of Acetylcholine Receptors at Neuromuscular Junctions: Analysis by Specific AntibodiesAnnals of the New York Academy of Sciences, 1987
- Synthetic Peptides and Their Antibodies in the Analysis of the Acetylcholine ReceptoraAnnals of the New York Academy of Sciences, 1987
- Immunopathogenesis and treatment of myasthenia gravisJournal of Clinical Immunology, 1987
- Acetylcholine Receptor Antibodies and Anti‐Idiotype Antibodies Produced in Blood Lymphocyte Cultures from Patients with Myasthenia GravisScandinavian Journal of Immunology, 1986